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Abstract 
Current treatment approaches for esophageal cancer are associated with a poor survival, and 
there are ongoing efforts to find new and more effective therapeutic strategies. There are several 
reports on the anti-tumoral effects of low molecular weight heparin (LMWH). We have assessed 
the possible survival benefit of LMWHs in esophageal malignancies. This was a randomized, 
single blind, multi-center, phase II clinical trial on non-metastatic esophageal cancer candidate 
for neoadjuvant chemoradiotherapy. Patients were randomly assigned to the chemoradiotherapy-
only arm or chemoradiotherapy plus enoxaparin arm using 1:1 allocation. Radiotherapy was 
delivered in 1.8-Gy daily fractions to a dose of 50.4 Gy in both groups. Paclitaxel 50 mg/m2 and 
carboplatin (AUC 2) were administered weekly concurrent with radiotherapy. In the intervention 
group, patients received enoxaparin (40 mg) daily as well as chemoradiation. Four to six weeks 
after treatment, all patients underwent esophagectomy. After a median follow up of 7 months, 
estimated one year disease free survival (1y DFS) in the intervention group was 78.9% and in the 
control groups was 70% (p=0.5). Toxicity from the experimental treatment was minimal and 
there were no treatment-related deaths. A Pathologically complete response in intervention and 
control group was 64.8% and 62.5%, respectively (p=0.9). There was a non-significant trend 
toward improved survival by the addition of enoxaparin to the concurrent chemoradiotherapy 
regimen. However, 1y DFS of both groups were high as expected. A longer follow-up and larger 
sample size is required. 
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1. Background 
Currently, a multimodal approach (neoadjuvant chemotherapy and/ or radiation therapy, 
followed by esophagectomy) is considered to be the standard of care for the treatment of thoracic 
esophageal cancers; however, 5-year survival rates remain poor at between 12–20% (De Angelis 
et al., 2014; Siegel et al., 2016). Neoadjuvant treatment leads to an increased likelihood of 
complete surgical resection (R0 resection), improved local control and modestly ameliorates 
disease-specific and overall survival; it also allows an evaluation of the effectiveness of the 
treatment regimen for each clinical scenario (Posner et al., 2015). The most contemporary 
published randomized controlled trials (RCT) that inform current clinical practice are the: 
ChemoRadiotherapy for Oesophageal cancer followed by Surgery Study (CROSS) (Shapiro et 
al., 2015), Medical Research Council (MRC) Adjuvant Gastric Infusional Chemotherapy 
(MAGIC) (Cunningham et al., 2006), the Fédérale Nationale des Centres de Lutte Contre Le 
Cancer (FNLCC) ACCORD (Ychou et al., 2011), and MRC OEO2  (Allum et al., 2009; Medical 
Research Council Oesophageal Cancer Working Group, 2002) studies. Currently, phase II and 
III trials focus on determination of the optimal components of the neoadjuvant therapies that lead 
to introduction of targeted therapies and immune based approaches in the treatment of 
esophageal cancer (Anvari et al., 2017; Bang et al., 2010). One agent that has attracted recent 
attentions, is low molecular weight heparins (LMWHs) that has been historically used for 
treatment of cancer induced deep venous thrombosis (DVT) (National Comprehensive Cancer 
Network, 2011). There are several reports on the anti-tumoral effects of LMWH. We have 
assessed the possible survival benefit of LMWHs in esophageal malignancies. 
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2. Methods 
2.1. Trial Design 
This was a multicenter, stratified (with balanced randomisation [1:1]), parallel-group phase II 
clinical trial conducted at three sites in northeastern Iran: The Emam Reza Hospital, Omid 
Hospital, and Reza Radiotherapy and Oncology Center in Mashhad from July 2016 to February 
2018. The study was approved by the Ethics Committee of Mashhad University of Medical 
Sciences (reference number: MUMS.fm.REC.1395.53). The ethical rules of research according 
to Helsinki Declaration were observed and all patients signed a written consent form. The 
protocol of study was registered in the Iranian Registry of Clinical Trials 
(IRCT2016070628814N1) and ClinicalTrials.gov (NCT03254511). 
2.2. Participants 
Eligible participants were adults aged ≥18 years with squamous cell carcinoma (SCC) of 
esophagus who met the eligibility criteria for neoadjuvant chemoradiation and definitive 
esophagectomy (non-metastatic SCC of thoracic esophagus). Patients also had to have adequate 
hematologic, renal, hepatic, and pulmonary function. Primary exclusion criteria were pregnancy 
and lactation, previous history of chemotherapy or chest-wall irradiation, history of major 
comorbidities (including liver or renal failure), adenocarcinoma or small cell carcinoma of 
esophagus, or the presence of synchronous cancer.  Enoxaparin is contraindicated if the patient 
has a condition with a high risk of haemorrhage. Secondary exclusion criteria were patient's 
refusal to agree to an esophagectomy and Eastern Cooperative Oncology Group (ECOG) 
performance status score ≥3 during neoadjuvant treatment.  
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2.3. Staging 
Before treatment, all patients underwent diagnostic and staging work-up. This included taking a 
history; physical examination; routine hematologic and biochemical tests; upper gastrointestinal 
endoscopy with histologic biopsy; and computed tomography of the neck, chest, and upper 
abdomen. In case of presence of suspected cervical lymph nodes, ultrasonography of the neck, 
with fine-needle aspiration was performed. Patients did not undergo esophageal endoscopic 
ultrasound with fine-needle aspiration because of the prohibitive costs of a US-guided 
endoscopic approach which limits their widespread availability in Iran. 
2.4. Interventions 
Patients were randomly assigned to receive neoadjuvant chemoradiation alone or neoadjuvant 
chemoradiation plus enoxaparin. Radiotherapy was prescribed with a total dose of 50.4 Gy that 
was given in 28 fractions of 1.8 Gy each, with 5 fractions administered per week. Chemotherapy 
was administered weekly concurrent with radiotherapy that was consisted of carboplatin targeted 
at an area under the curve of 2 mg per milliliter per minute and paclitaxel at a dose of 50 mg per 
square meter of body-surface area intravenously. Before injection of paclitaxel, all patients were 
premedicated with intravenous dexamethasone, chlorpheniramine, and ranitidine as well as 
standard antiemetic agents. In the chemoradiation plus enoxaparin group, patients received 
enoxaparin sodium 40 mg/ 0.2 ml subcutaneous injection once daily during chemoradiation. This 
dose was chosen based on a review of the literature (Javadinia et al., 2018). Patients were 
monitored closely for possible side effects of chemotherapy or enoxaparin. Within 4 to 6 weeks 
after completion of neoadjuvant treatment, patients underwent esophagectomy. During the 
waiting period for esophagectomy, patients underwent upper gastrointestinal endoscopy for the 
assessment of the clinical response of the tumor to the neoadjuvant treatment.  
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2.5. Outcomes  
The primary endpoints were clinical response, pathological response and R staging. Clinical 
response was defined as complete clinical response (no tumoral lesion), significant clinical 
response (a substantial reduction in the size of tumor, more than 50%), and poor clinical 
response (persistent lesion or reduction size of lesion less than 50%), based on preoperative 
upper gastrointestinal endoscopy. Pathologic response was defined as pathologic complete 
response (no evidence of vital residual tumor cells) and persistent disease (presence of any 
degree of vital residual tumor cells) based on pathologic evaluation of esophagectomy specimen. 
Residual staging (R staging) was classified according to the report of surgery and pathology. 
Any gross residual disease was considered to be R2 resection while microscopically positive 
margins were considered to be R1 resection. If there was neither a gross residual disease nor a 
microscopically positive margin, the surgery was considered to be R0 resection. The secondary 
endpoint was disease free survival which was considered over the length of time after 
esophagectomy, that the patient survived without any signs or symptoms of esophageal cancer 
(local or distal recurrence). Common Terminology Criteria for Adverse Events (CTCAE) v5.0 
was used for reporting the adverse events.  
2.6. Sample size and randomisation 
Sample size was determined as at least 40 patients in each group based on confidence interval 
(CI): 95%, power: 80%, and effect size 45%. For allocation of the participants, a computer-
generated list of random numbers was used with blocked randomisation [1:1]. 
2.7. Statistical methods 
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Data were analysed using Statistical Package for the Social Sciences (SPSS) version 20.0 by the 
Mann–Whitney U, the Chi-Square, and Fisher's exacts. The Kaplan–Meier method was used to 
estimate survival, with the log-rank test to determine significance. P value≤0.05 was considered 
significant. 
3. Results 
3.1. Characteristics of patient  
Between June July 2016 to February 2018, 69 patients from three participating centers (two 
academic centers and one large non-academic teaching hospital) were randomly assigned to 
neoadjuvant chemoradiation plus enoxaparin arm (n=37) or chemoradiation alone arm (n=32). 
The Consolidated Standards of Reporting Trials (CONSORT) diagram summarizes patient status 
(Figure 1). Both groups were similar in term of age, gender, ECOG performance score, tumor 
grade, and location tumor. Table 1 summarizes the data on demographic and baseline disease 
characteristics.  
3.2. Outcomes and estimation 
For the assessment of clinical response, preoperative endoscopy was requested. One patient in 
each group refused to consent.  Complete clinical response was reported in 14 out of 36 patients 
of the chemoradiation plus enoxaparin arm and 11 out of 31 patients of chemoradiation alone 
arm (p=0.5). All patients in both arms had an R0 resection. After esophagectomy pathologic 
evaluation revealed higher portion of complete pathologic response in the chemoradiation plus 
enoxaparin arm (64.8% vs. 62.5%, p=0.9). Table 2 shows the difference of responses between 
the two groups. One years DFS was higher among patients who received chemoradiation plus 
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enoxaparin (78.9% vs. 70%, p=0.5). Figure 2 shows Kaplan–Meier plots of estimated 3-year 
disease free survival. 
3.3. Adverse effects 
One patient in the chemoradiation plus enoxaparin arm was excluded from the study due to 
severe thrombocytopenia. Similarly, in the chemoradiation alone arm, one patients was excluded 
due to severe pancytopenia during the study. The proportion of patients experiencing any adverse 
event was relatively higher in the chemoradiation plus enoxaparin arm (9/37 vs. 2/37, p=0.02); 
however, all adverse effects in both groups were related to the chemotherapy (all of them were 
neutropenia, the grade 1-2 in case and control group was 15.6% and 3.1% and grade 3-4 was 
10.8% and 3.1%, p=0.03). Except patients who were excluded, no other serious adverse events 
were reported. 
4. Discussion 
This study was undertaken to investigate the effects of adding enoxaparin to neoadjuvant 
chemoradiotherapy in esophageal cancer. In the intervention group, daily prescription of 40mg 
enoxaparin was added to chemoradiotherapy [EBRT: 50Gy/2Gy, once daily, five days in week 
concurrent with paclitaxel (50 mg/m2) +carboplatin (AUC=2) weekly)]. Altogether, results of 
present study showed that there was a non-significant trend to improvement in the clinical and 
pathologic response in patients who were treated with enoxaparin. In addition concurrent 
neoadjuvant chemoradiotherapy with enoxaparin led to an improvement of1y DFS and a 7 month 
increase in the median survival. Although the difference was nonsignificant. 
Despite the several studies reporting antitumoral effects and survival advantages of anticoagulant 
treatment, and specifically LMWH, in patients with cancer such as breast (Mellor et al., 2007) 
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lung (Altinbas et al., 2004; Bobek et al., 2005) and  high grade brain gliomas (Perry et al., 2010),  
these effects have not be investigated in esophageal cancer and the present study appears to be a 
novel one. 
Early studies by Bell et all (Bell, 1978), DiPalma et all (DiPalma and McMichael, 1979), and 
Hilgard et al (Hilgard and Thornes, 1976) have shown the potential effects of heparin against 
angiogenesis, and thereby, against transplanted tumor tissue growth at cellular level, which 
caused early  clinical trials about antitumoral effects of anticoagulant drugs, and resulted in three 
large trials Malignancy and Low Molecular Weight-Heparin Therapy (MALT) (Klerk et al., 
2005), Fragmin Advanced Malignancy Outcome Study (FAMOUS) (Kakkar et al., 2004),and 
CLOT (Lee et al., 2005) between 2004 and 2005. These studies show that LMWHs causes an 
improvement in survival in patients with cancer, independent of their antithrombotic effect 
(Kakkar et al., 2004; Klerk et al., 2005; Lee et al., 2005). 
In an earlier trial, the MALT, patients with advanced malignancy were randomly divided into 
two groups: placebo (n=154) and nadroparin (n=148) and treated for 6weeks. Enrolled patients 
in this study were mostly patients with adenocarcinoma, and most had breast, lung and/or 
colorectal cancers. In the 12 months follow-up, the HR for death was 0.75 (95% CI:0.59-0.96) 
and median survival in nadroparin and placebo were 8  and 6.6 month, respectively, significantly 
improved in treated patients with nadroparin (Lee et al., 2005). The efficacy of one year 
treatment with dalteparin was evaluated in the FAMOUS trial (Kakkar et al., 2004). As in 
MALT, most of participants of the FAMOUS suffered from advanced malignancy (stage III or 
IV), mostly breast, colorectal, and ovarian cancer. Results of Kaplan-Meier survival analysis did 
not show any survival improvement, after one, two and three year, although patients who 
survived at least 17 month, appeared to benefit from treatment with dalteparin (two and three 
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year survival 78% vs 55% and 60% vs 36% respectively, p=0.03)(9). This study, importantly, 
showed that survival benefit of dalteparin persisted even after discontinuation of the drugs that 
translate into possible antitumoral effects of LMWHs, independent from their antithrombotic 
effects. In the CLOT trial, over 600 patients with simultaneous cancer and DVT were treated 
with warfarin or dalteparin for about six month. In non-metastatic patients, use of LMWHs was 
associated with improved survival and decreased mortality rate [mortality rate in LMWH and 
warfarin groups was 20% and 36%, respectively (HR 0.50; 95% CI: 0.27-0.95; p=0.03)]. In 
patients with metastatic disease, there were no survival benefits (HR 1.1; 95% CI: 0.87-1.4; 
p=0.46) (Lee et al., 2005). 
Nonetheless previous studies reported survival benefits of warfarin (Schulman and Lindmarker, 
2000; Zacharski et al., 1981) and decreased in incidence of new cancers in patients with cancer 
(Tagalakis et al., 2007) but one meta-analysis that compared mortality following treatment with 
warfarin or LMWHs in 11 clinical trials, only LMWHs were associated with improved survival 
(RR 0.877;95% CI:0.789-0.975;p=0.015); however, this effect was not observed with warfarin 
(RR 0.942;95% CI: 0.854-1.040; p=0.239) (Kuderer et al., 2007). A recent systematic review 
show that using heparin in cancer patients was associated with improved survival (HR 0.77, 95% 
CI 0.65-0.91) (specifically in patients with early stage disease) without increasing the risk of 
hemorrhagic events (RR 1.78,95% CI0.73-4.38) (Akl et al., 2007). It seems that LMWHs have 
potential role in improvement of survival in a subgroup of patients with cancer, although more 
investigations are needed to detect the rate and mechanisms of their efficacy according to the 
type, site and stage of disease. 
There are controversies regarding possible effects of LMWHs in the management of cancerous 
patients (with goal of improvement of survival). For example, two  relatively/quite large clinical 
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trials investigation the antitumoral effects of the ultra-low molecular weight heparins, 
Semuloparin (Agnelli et al., 2012) and nadroparin (Agnelli et al., 2009), did not show any 
survival benefit compared to LMWH. It is noteworthy that the major problem of most of 
previous research was heterogeneity in patients (Akl et al., 2007). Some studies in homogeneous 
patients with solid tumors like breast (Haas et al., 2012), malignant glioma (Perry et al., 2010) 
and lung cancer (Macbeth et al., 2015), were also, unable to show clinical benefits from adding 
LMWH to the standard treatment of cancerous patients. 
Despite these controversies about the survival advantages of LMWH in solid tumors, in two 
recent review studies by Akl et al (2014) (Akl et al., 2014) and Zhang et al (2016) (Zhang et al., 
2016), the authors concluded that LMWHs have clinical benefits in survival improvement of 
patients with cancer and considering the low risk of hemorrhagic events associated with 
combination of LMWHs and other chemotherapeutic agents, future investigation in evaluating 
different LMWH efficacies on different pathologies is warrant. However, it should be noted that 
according to current evidence, no guidelines recommend the use of LMWHs in order to improve 
survival of cancer patients and this indication is off-label (Geerts et al., 2008; Lyman et al., 2007; 
Mousa, 2006; National Comprehensive Cancer Network, 2011). 
Clinical trials investigation the benefits of different types of LMWHs in the treatment of solid 
tumors, several studies have looked at the underling molecular mechanisms of these drugs. Each 
LMWH has special structural profile which causes unique pharmacokinetics and 
pharmacodynamics related to the drug structural differences between LMWHs including 
molecular weight, size, end component, carboxyl to sulfate ratio, and adhesive part of anti-Xa 
ratio, that have an effect on their biological activity (Fareed et al., 2004; Jeske et al., 2008). 
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Currently, there are ongoing studies in order to detecting/distinguishing antitumoral and 
antimetastatic features of these drugs (Casu et al., 2007). 
It appears that the improvement in survival of patients with cancer, when using LMWHs, is not 
merely due to a reduction in the risk of DVT and pulmonary embolism, but due to the anti-
tumoral effects of these drugs. LMWHs influence cancer cell growth directly by interfering in 
the coagulation cascade or hypothetical mechanisms (including anti-proliferative functions) 
(Balzarotti et al., 2006), and indirectly by modulatory effects of mucopolysaccharides chains on 
cell signaling and the cell/environment interactions, and on enzymes and cell-signaling 
molecules (Mousa, 2006). Anti-tumoral effects of low molecular weight heparin is mainly 
through inhibition of  the interactions between P selectin of platelet and P selectin ligands on the 
surface of tumor cell that causing formation of the tumor cell-platelet complex. Via their P-
selectin, platelets interact with both the endothelium and tumor cells helping their extravasations 
to the vascular compartment (figure 3) (Javadinia et al., 2018). 
Furthermore, glycosaminoglycans or mucopolysaccharides chains cause the anti-metastatic 
effects of these drugs by interfering in the P-selectin mediated tumor metastasis pathway, and 
this is confirmed by lack of anti-metastatic effects in fundaparinox (a LMWH without 
mucopolysaccharides chain) (Stevenson et al., 2005). Beside the anti-tumoral effects of 
LMWHs, these drugs also possess anti-angiogenic effects as well  (Folkman et al., 1983), and 
cause dose dependent anti-angiogenesis effects by simulating the endothelial tissue inhibitory 
pathways, and leading to inhibitory effects on tissue factors (Coughlin, 2005; Mitroulis et al., 
2011; Norrby, 2006). As well as the anti-tumoral effects of heparins through inhibition of growth 
and angiogenesis, they can also directly affect the immune system by inhibitory effects on 
extravasation of leucocytes and the complement system, or increasing the sensitivity of tumoral 
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cells to immunological attack (Coughlin, 2005; Handa et al., 1991; Itoh et al., 1995; Mitroulis et 
al., 2011; Mousa and Mohamed, 2004; Norrby, 2006; Stevenson et al., 2005),  therefore 
influence the anti-tumoral immunologic processes (Zhang et al., 2016). 
Overall, the results of present study indicate that integration of enoxaparin into chemoradiation 
protocol is safe and tolerable. However, higher probability of neutropenia was reported in the 
patients treated with enoxaparin (no febrile neutropenia was reported in both groups). There are 
reports showing that neutropenia was greater in patients treated with chemotherapy + LMWH 
compared with those treated with chemotherapy alone (Altinbas et al., 2004). Also, the data are 
conflicting and Kucukoner et al. (2012) observed that neutropenia occurred more in patients 
treated with chemoradiation alone compare to patients received  LMWH as well (Kucukoner et 
al., 2012).  
The treatment of patients with esophageal SCC remains controversial since most previous 
investigations that determine our current practice, are fully adopted from the treatment 
approaches of developed countries that current effort try to overcome these uncertainties. A 
further positive aspect of our study was the evaluation of LMWHs anti-tumoral properties in a 
relatively homogenous population (with respect to disease type and histology). Limitations of 
our study were the lack of chemotherapy in a number of intervention group, which is associated 
with a reduction in the chemosensitizer effects of the indicated drugs and failure in monitoring of 
anti-Xa levels during the study. Considering the various effects of LMWHs in the inhibition of 
several pathways of tumors cell growth and metastasis and a possible a direct antitumor effect of 
LMWHs (e.g. a direct interference with components of the coagulation cascade), it is suggested 
that further studies should be conducted with higher sample size and considering the anti-Xa 
levels monitoring during the study and pattern of recurrence and metastasis in patients. Also, 
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regarding that cellular investigations indicate to dose dependent anti-tumoral properties of 
LMWHs, it is suggested that different dosages of these combinations should be 
experienced/tested in future researches.  
5. Conclusion 
Overall, the results of this study showed that the clinical and pathological response of squamous 
cell carcinoma of esophagus to the neoadjuvant chemoradiation was improved by the addition of 
enoxaparin to the treatment, although the difference was not significant. Also, there was an 
insignificant improvement in one year disease free survival of chemoradiotherapy patients 
receiving enoxaparin. Data from our study indicate that concurrent enoxaparin with radiotherapy 
and weekly paclitaxel/carboplatin chemotherapy was associated with minimal toxicity. The 
effects of LMWHs on survival of cancer patients, is probably due to a combination of direct anti-
tumoral effects, antiangiogenic and immunomodulatory effects, beside indirect effects on the 
coagulation system. Most of these direct and indirect effects may have clinical efficacy in the 
treatment of SCC and gasteroesophageal adenocarcinoma, although the current data on this are 
contradictory and the observed benefits have been mostly from cellular and in-vitro 
investigations. Considering that treatment with LMWHs has few side effects, it is recommended 
that efforts to define the mechanisms of this group of these drugs in affecting tumor growth in 
the cellular level, and also clinical trials on the benefits of the anticoagulant and anti-tumoral 
effects, should be continued. However, it must be noted that the new generation of LMWHs lack 
the oligosaccharide segment and thus part of the antitumoral effects of these drugs may be 
limited. 
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Table 1. Patient and tumor characteristics per treatment group 
  CRT+enoxaparin CRT alone P value 
Variables   Frequency (%) Frequency (%) 
Age (years)
†
 60  ≥  13 (35.1) 8 (25) p=0.4 
 61< 24 (64.9) 24 (75) 
 
Gender
†
 Female 18 (48.7) 15 (46.8) p=0.8 
 Male 19 (51.3) 17 (53.2)  
ECOG PR
†
 0-I 37 (100) 32 (100) - 
 II 0 (0) 0 (0)  
Tumor location
‡
 Upper  thoracic 1 (2.7) 2 (6.3) p=0.3 
 Middle thoracic 21 (56.8) 13 (40.6)  
 Lowe thoracic 15 (40.5) 17 (53.1)  
Tumor grade
 †
 I-II 29 (78.4) 25 (78.1) p=0.8 
 III-IV 8 (21.6) 7 (21.9)  
CRT: chemoradiation, ECOG PR: Eastern Cooperative Oncology Group (ECOG) performance status 
score,
 †
Chi-Square test revealed no significant difference, 
‡
Fisher's exact test revealed no significant 
difference. 
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Table 2. The difference of clinical and pathologic responses between two groups 
  CRT+enoxaparin CRT alone P value 
Variables   Frequency (%) Frequency (%) 
Clinical response
‡
 CCR  14 (38.9) 11 (35.5) p=0.5 
 SCR 21 (58.3) 17 (54.8) 
 
 PCR 1 (2.8) 3 (9.7) 
 
Classification of clinical response
 †
 CCR 14 (38.9) 11 (35.5) p=0.8 
 RM 22 (61.1) 20 (64.5)  
Pathologic response
†
 pCR 24 (64.8) 20 (62.5) - 
 PD 13 (35.2) 12 (34.8)  
R staging
†
 R0 res 37 (100) 32 (100) - 
 R1 res 0 (0) 0 (0)  
 R2 res 0 (0) 0 (0)  
CCR: complete clinical response, SCR: significant clinical response, PCR: poor clinical response, pCR:  
pathologic complete response, PD: persistent disease. RM: residual mass, res: resection. Classification of 
clinical response based on CCR vs SCR+PCR. 
†
Chi-Square test revealed no significant difference, 
‡
Fisher's exact test revealed no significant difference. 
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Figure 2. Kaplan–Meier Plots of Estimated 1-Year Disease Free Survival  
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Figure 3: Anti-tumoral effects of low molecular weight heparin. a) Through the interactions between P 
selectin of platelet and P selectin ligands on the surface of tumor cell, the tumor cell-platelet complex is 
formed and causes dissemination. Via their P-selectin, platelets interact with both the endothelium and 
tumor cells helping their extravasations to the vascular compartment. b) LMWHs block the interaction 
between cancer cells and platelet and prevent the formation of tumor cell-platelet complex resulting in 
inhibition of metastasis.  
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